Their meta-analysis showed that a reduced risk for MACE with GLP-1RA was consistent in patients receiving SGLT2i (HR = 0.77) and those not (HR = 0.79
Some may consult with a professional regarding creating a plan to help improve weight management
Practical implications For patients who develop allodynia on one GLP-1 medication, switching to a different medication within the class (or to a different formulation of the same medication) is a reasonable strategy to try
Information provided is for general lifestyle guidance only and is not medical, financial, or professional advice
Some people with diabetes choose to use a tighter range of 70-140 mg/dl, though 70-180 mg/dl is a good starting point for many
GLP-1s, short for glucagon-like peptide-1 agonists, are prescription medications originally approved to treat type 2 diabetes